For decades, families heard the same sentence when Alzheimer’s disease entered the room: there is nothing to be done but manage the decline. This year’s World Alzheimer Report says that sentence is no longer true. Published by Alzheimer’s Disease International to mark World Alzheimer’s Day, the 2026 report argues that after years of slow progress, clinical trials are on the brink of diagnostic and medical breakthroughs, and that the disease is “no longer universally described as untreatable.” It is one of the most hopeful documents the dementia field has produced in a generation.
The turning point
The shift is real, and it has a name: donanemab and lecanemab. These are the first fully approved treatments shown to modestly slow early Alzheimer’s decline rather than merely easing symptoms. They work by targeting and clearing the amyloid plaque that builds up in the brains of people with Alzheimer’s years before symptoms appear. Both have now been approved in multiple countries; in Australia, regulators approved donanemab in May 2025 for mild cognitive impairment due to Alzheimer’s, with lecanemab following in September 2025.
“Modestly” is doing honest work in that sentence, and the report does not oversell it. A cure remains far away. But Cath Mummery, director of the UK’s Dementia Trials Network, described the new drugs in the report as “the first brick,” and bricks are how walls get built. The pipeline behind them is the real story: 158 potential therapies are now being tested across 192 clinical trials worldwide, a rise of roughly 40 percent over the past decade. Eight Phase III trials are expected to report results during 2026. About three-quarters of the medicines in development are designed to modify the underlying disease process, not just mask symptoms.
Prevention is moving to the center
Perhaps the most consequential finding is not about drugs at all. The report highlights growing evidence that a large share of dementia cases could be delayed or prevented by addressing modifiable risk factors, as many as 14 of them, including high blood pressure, depression, physical inactivity, smoking, diabetes, alcohol use, and high cholesterol. Researchers increasingly treat Alzheimer’s the way cardiology treated heart disease a generation ago: as a condition you can see coming and work against.
Dr. Campbell Le Heron, a neurologist and Alzheimers NZ spokesperson, put it plainly: for a long time there has been what he called a fairly nihilistic view in the dementia world, the idea that cognitive decline just happens with age and nothing can be done. “These trials are showing us that we can potentially do something about it, at least in certain situations,” he said. “Our biological understanding of the condition is identifying ways we can actually prevent it.”
The hard part: finding volunteers
The report is also candid about the bottleneck. Trials need people, and dementia trials are picky: specific disease stages, proof of Alzheimer’s-related proteins, the absence of certain other conditions, a study partner. About 55,000 participants are needed, and because so many volunteers fail screening, researchers estimate that as many as 350,000 people may need to step forward. The report’s conclusion on this point is worth quoting: taking part in dementia research should depend on “realistic opportunity for everyone who wishes to consider it,” not on persistence or good fortune.
This is where families come in. Practical steps exist right now. Anyone can search ClinicalTrials.gov by condition and location, or use the Alzheimer’s Association’s TrialMatch service, to find studies nearby. Healthy volunteers are wanted too, not just people with symptoms. And the everyday prevention advice keeps getting stronger: control blood pressure, stay active, protect your hearing, stay socially connected, treat depression. It echoes the research into brain blood flow in Alzheimer’s risk groups that is quietly building the case for early action, and it sits alongside the encouraging long-term data for lupus treatment as evidence that chronic disease medicine is having a genuinely good year.
What changes now
Numbers give the report its weight. More than 55 million people were living with dementia worldwide as of 2019, and the figure is projected to pass 139 million by 2050 as populations age. Dementia is becoming one of the leading causes of death on the planet. Against that backdrop, the report’s central claim, that we stand “on the cusp of a giant leap forward at the intersection of innovation in diagnostics, treatments, and risk reduction,” reads less like hype and more like arithmetic. The investment is there. The pipeline is there. The volunteers are the missing piece.
Chris Lynch, the acting CEO of Alzheimer’s Disease International, wrote in the report: “Never before has there been so much focus, investment, and hope in dementia research.” Hope is not a treatment. But for the families who have been told for years that nothing could be done, a major global report saying otherwise, with 158 therapies in trials to back it up, is the beginning of a different conversation. The next decade of dementia care will be built by the people who show up for it, in clinics and in trials. That is something all of us can be part of.
